Search Medical Condition
Please enter condition
Please choose location from dropdown

Epargny Metz-Tessy, France Clinical Trials

A listing of Epargny Metz-Tessy, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (123) clinical trials

Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers

Hemodialysis patients will be randomized in 2 arms: one arm where persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers in this arm will be done every 3 ...

Phase

3.26 miles

Learn More »

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Adult patients aged 18 years with stage IV lung cancer and elevated D-dimer will be randomized to the experimental or control group.Patients in the control group will receive usual care, patients in the experimental group will receive subcutaneous tinzaparin once daily for six months. Follow-up visit will take place in ...

Phase

3.26 miles

Learn More »

Protection During Cardiac Surgery.

This trial investigates whether a multimodal cardioprotection per-surgery therapeutic strategy could reduce myocardial injury in patients undergoing cardiac surgery compared to traditional management. The primary endpoint is the AUC (area under the curve) of the hypersensitive troponin I. Blood samples will be collected during the 72 hours following the aortic ...

Phase N/A

3.26 miles

Learn More »

Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation

In this context, all measures that will reduce the risk of infection, will improve the prognosis of these patients. Thus, recent studies have shown greater effectiveness of local preparation for alcoholic chlorhexidine (applicator containing 2% chlorhexidine and 70% alcohol isopropanolol) (AC 2%) compared to the aqueous povidone iodine (API)in general ...

Phase

3.27 miles

Learn More »

WAMIF : Young Women Presenting Acute Myocardial Infarction in France

Cardiovascular disease is the leading cause of death among women in France. In-hospital mortality after acute coronary syndrome (ACS) remains significantly higher than in men, with a relative risk of up to 150%, especially among young women1,2. Early mortality rate of myocardial infarction (MI) continues to decline but that of ...

Phase N/A

3.27 miles

Learn More »

Bone Fixation of Mpact Double Mobility Cup

This study aims to evaluate long term fixation of the Mpact Double Mobility cup trough IMAGIKA technology.

Phase N/A

3.27 miles

Learn More »

Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

This is a randomized multicentre study in patients with high-risk MIBC to investigate adjuvant radiotherapy after radical cystectomy and pelvic lymph node dissection. The objective of the study is to provide evidence that adjuvant radiotherapy improves loco-regional control with potential benefits in survival. The study will also evaluate the quality ...

Phase N/A

3.27 miles

Learn More »

Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

WHO. WHO Global Strategy for Containment of Antimicrobial Resistance.: World Health Organization, 2001. Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis 2010;23(4):346-58. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant ...

Phase

3.27 miles

Learn More »

Contribution of a Clinical Pathway for the Treatment of Hip Prosthesis Infections

The incidence of surgical site infections following the orthopedic surgery is about 1%. The number of prosthesis infections is estimated between 2000 and 2500 new cases a year in France. Multiple medical and surgical care strategies are possible depending on the acute or chronic presentation, early or delayed antibiotic therapy; ...

Phase N/A

3.27 miles

Learn More »

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

This study will take place in several periods and phases of treatment: Observational period of selection of 28 days maximum Treatment period constituted: a first phase of treatment with ibrutinib alone (28 days): pre-phase, a formal protocol phase during which the two study drugs (ibrutinib and daratumumab) will be used ...

Phase

3.27 miles

Learn More »